Halozyme Therapeutics (NASDAQ: HALO) and GW Pharmaceuticals PLC- (NASDAQ:GWPH) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Earnings and Valuation

This table compares Halozyme Therapeutics and GW Pharmaceuticals PLC-‘s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Halozyme Therapeutics $146.69 million 18.91 -$103.02 million ($0.68) -28.66
GW Pharmaceuticals PLC- $11.00 million 282.09 -$166.90 million ($6.72) -18.24

Halozyme Therapeutics has higher revenue and earnings than GW Pharmaceuticals PLC-. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than GW Pharmaceuticals PLC-, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Halozyme Therapeutics and GW Pharmaceuticals PLC-, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halozyme Therapeutics 1 3 3 0 2.29
GW Pharmaceuticals PLC- 0 2 6 0 2.75

Halozyme Therapeutics currently has a consensus price target of $18.00, suggesting a potential downside of 7.64%. GW Pharmaceuticals PLC- has a consensus price target of $146.25, suggesting a potential upside of 19.34%. Given GW Pharmaceuticals PLC-‘s stronger consensus rating and higher possible upside, analysts plainly believe GW Pharmaceuticals PLC- is more favorable than Halozyme Therapeutics.

Risk and Volatility

Halozyme Therapeutics has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500. Comparatively, GW Pharmaceuticals PLC- has a beta of 2.65, suggesting that its stock price is 165% more volatile than the S&P 500.

Profitability

This table compares Halozyme Therapeutics and GW Pharmaceuticals PLC-‘s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Halozyme Therapeutics -53.17% -892.57% -29.67%
GW Pharmaceuticals PLC- -1,607.85% -40.42% -34.97%

Insider & Institutional Ownership

84.5% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 81.9% of GW Pharmaceuticals PLC- shares are held by institutional investors. 16.8% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Halozyme Therapeutics beats GW Pharmaceuticals PLC- on 7 of the 13 factors compared between the two stocks.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant. The Company’s development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company’s commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.